Annual Report

Overview

The report presents Beximco Pharma's 2022-23 consolidated net sales of BDT 39,266.7 million, an increase of 13.3% year on year. It also describes an EHS Committee, environmental initiatives including water reuse and rooftop solar generation, and extensive occupational health and safety measures. The people section reports a parent-company workforce of 5,706 employees and 8,754 specialized training man-hours involving 605 team members. The report also records 14 new domestic generics and 33 new registrations of 19 generics across 17 overseas markets.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022-2023
Period: 1 July 2022 – 30 June 2023
Language: English
Pages
File size

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services